AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Pharmacyclics (PCYC) Imbruvica CLL Update a Positive for Suitor Abbvie (ABBV) - BMO Capital
April 20, 2015 3:25 PM EDTBMO Capital analyst Alex Arfaei reiterated his Outperform rating and $68 price target on Abbvie (NYSE: ABBV) as Pharmacyclics' (NASDAQ: PCYC)... More
